Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabichromene
- Development stage
- Phase 2
- Modality
- Small Molecules
- Administration
- Oral, Sublingual, Topical, Inhalation, Transdermal
01
Overview
Cannabichromene is a non-psychoactive phytocannabinoid found in the Cannabis plant. It is one of the most abundant cannabinoids after THC and CBD. Cannabichromene acts primarily as a selective agonist at the Cannabinoid receptor type 2 (CB2) and has low affinity for CB1 receptors. It also activates Transient receptor potential ankyrin 1 channel (TRPA1) and Transient receptor potential vanilloid 1 channel (TRPV1), which are involved in pain perception and inflammation. Preclinical studies suggest that CBC exhibits modest antinociceptive (pain-reducing), anti-inflammatory effects, neuroprotective properties, anticonvulsant activity in animal models, and may inhibit cancer cell growth in vitro. Its mechanism includes modulation of endocannabinoid tone by inhibiting cellular reuptake of endocannabinoids and weak inhibition of monoacylglycerol lipase (MAGL). There are currently no FDA-approved medications based on CBC[1][3][4][5][6][7].
- Brand names
- Prodiol CBC
- Other names
- CBCcannabichromecannanbichromenepentylcannabichromenecannabinochromene
02
Targets
CNR1 (Cannabinoid receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPA1 (Transient receptor potential cation channel subfamily A member 1)
Beyond the preview
Go deeper on cannabichromene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabichromene.